NCT07245862 Evaluation of a Family-centered Program for Problematic Gaming/Excessive Screen Use
| NCT ID | NCT07245862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Skane |
| Condition | Adolescent Behavior |
| Study Type | INTERVENTIONAL |
| Enrollment | 170 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 170 participants in total. It began in 2026-01-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Family-Centered Program for Problematic Gaming and Excessive Screen Use (FAME) is a pioneering initiative designed to address the growing challenges of excessive screen use and gaming among children and adolescents, particularly within family dynamics.
Eligibility Criteria
Inclusion Criteria: * family conflicts related to screen use * spaeks and udnerstand swedish Exclusion Criteria: * se above
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07245862 clinical trial?
This trial is open to participants of all sexes, aged 11 Years or older, up to 14 Years, studying Adolescent Behavior. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07245862 currently recruiting?
Yes, NCT07245862 is actively recruiting participants. Contact the research team at emma.claesdotter-knutsson@skane.se for enrollment information.
Where is the NCT07245862 trial being conducted?
This trial is being conducted at Lund, Sweden.
Who is sponsoring the NCT07245862 clinical trial?
NCT07245862 is sponsored by Region Skane. The trial plans to enroll 170 participants.